{
    "clinical_study": {
        "@rank": "168135", 
        "arm_group": [
            {
                "arm_group_label": "Losartan", 
                "arm_group_type": "Experimental", 
                "description": "Losartan 50 mg bid orally"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 1 pill bid orally"
            }
        ], 
        "brief_summary": {
            "textblock": "The dual blockade of the renin-angiotensin-aldosterone system with an angiotensin-converting\n      enzyme inhibitor and an angiotensin-receptor blocker used together in heart failure patients\n      has been demonstrated to be beneficial. However, the dual inhibition has not been studied\n      during heart failure decompensation or even when low cardiac output is present.\n\n      The objective of this study was to assess the effects of add-on therapy with angiotensin\n      receptor blocker on plasma B-type natriuretic peptide levels and hemodynamic measurements in\n      heart failure patients with low cardiac output during hospitalization for decompensation.\n\n      This was a randomized, double-blind, placebo-controlled clinical trial."
        }, 
        "brief_title": "Losartan in Decompensated Heart Failure", 
        "completion_date": {
            "#text": "March 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Congestive Heart Failure", 
            "Low Cardiac Output"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cardiac Output, Low", 
                "Heart Failure"
            ]
        }, 
        "detailed_description": {
            "textblock": "The inclusion criteria were hospitalization for decompensated heart failure defined by\n      worsening of symptoms until fatigue or dyspnea at rest, low cardiac output defined by the\n      clinical-hemodynamic profile, dobutamine dependence, and ejection fraction < 0.45,\n      spontaneous breathing and receiving angiotensin-converting enzyme inhibitors. The patients\n      could have jugular ingurgitation, lower limbs edema, ascites and rales. Dobutamine\n      dependence was defined by infusion for more than 15 days or an unsuccessful attempt of\n      withdrawal.\n\n      The exclusion criteria were serum creatinine > 3.0 mg/dL, serum potassium > 6.0 mEq/L,\n      systolic blood pressure < 70 mm Hg, aortic stenosis, and acute coronary syndrome in the\n      previous 2 months. The patients were randomly assigned by permuted block of 4, stratified by\n      sex, to losartan or placebo.\n\n      The endpoints were change in B-type natriuretic peptide levels, cardiac index, pulmonary\n      wedge capillary pressure, systemic vascular resistance, and successful withdrawal of\n      dobutamine."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  hospitalization for decompensated heart failure\n\n          -  dobutamine dependence\n\n          -  ejection fraction < 0.45\n\n          -  taking angiotensin-converting enzyme inhibitor\n\n        Exclusion Criteria:\n\n          -  serum creatinine > 3.0 mg/dL\n\n          -  serum potassium > 6.0 mEq/L\n\n          -  systolic blood pressure < 70 mm Hg\n\n          -  aortic stenosis\n\n          -  acute coronary syndrome in the previous 2 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01857999", 
            "org_study_id": "INCOR 2993/07/008"
        }, 
        "intervention": [
            {
                "arm_group_label": "Losartan", 
                "intervention_name": "Losartan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Natriuretic Peptide, Brain", 
                "Losartan", 
                "Angiotensin Receptor Antagonists"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Renin-aldosterone system", 
            "Hemodynamic", 
            "Low cardiac output", 
            "Vasodilation", 
            "Natriuretic peptide"
        ], 
        "lastchanged_date": "May 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "S\u00e3o Paulo", 
                    "country": "Brazil", 
                    "state": "SP", 
                    "zip": "05021-010"
                }, 
                "name": "Cotox\u00f3 Hospital, Heart Institute (InCor), University of S\u00e3o Paulo"
            }
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Short-term add-on Therapy With Angiotensin Receptor Blocker for End-stage Inotrope-dependent Heart Failure Patients: B-type Natriuretic Peptide Reduction in a Randomized Clinical Trial", 
        "overall_official": {
            "affiliation": "Heart Institute (InCor), University of S\u00e3o Paulo", 
            "last_name": "Antonio P Barretto, Ph.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Serum B-type natriuretic peptide", 
            "measure": "B-type natriuretic peptide", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01857999"
        }, 
        "responsible_party": {
            "investigator_affiliation": "InCor Heart Institute", 
            "investigator_full_name": "Marcelo Eidi Ochiai", 
            "investigator_title": "Ph.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Successful withdrawal from dobutamine with clinical stability", 
                "measure": "Successful withdrawal from dobutamine", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Increase > 0.3 mg/dL in serum creatinine", 
                "measure": "Worsening renal function", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Serum potassium > 5.5 mEq/L", 
                "measure": "Hyperkalemia", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Systolic blood pressure < 80 mmHg", 
                "measure": "Hypotension", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }
        ], 
        "source": "InCor Heart Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InCor Heart Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2011"
    }
}